In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Benedict Cross, Chief Technology Officer at PhoreMost, a ...

Kyverna has previously reported positive midstage data with miv-cel in generalised myasthenia gravis (gMG), another ...

Tolebrutinib was one of three oral BTK inhibitors that Sanofi acquired as part of its $3.7 billion buyout of Principia ...

Among seven new medicines recommended for approval by the EMA's human medicine advisory committee at its latest meeting is ...

The latest judgment follows another setback in its defence in October, when a California jury awarded an eye-watering $966 ...

At the same time, the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG) has progressed, and the UK has ...

Omnichannel didn’t fail pharma. Our metrics did. In 2026, fixing that won’t be optional. It will separate teams that keep ...

Sobi has hit the acquisition trail with a deal to buy Arthrosi Therapeutics for up to $1.5 billion, adding a drug in late-stage clinical testing for gout.

The UK government has confirmed that the rebate rate for newer medicines supplied to the NHS under the Voluntary Scheme for ...

Today, the EU Council and Parliament reached an agreement in principle on the long-awaited pharma reform package, but ...

Chambers discusses her personal experience as a GP in the NHS, including the discrimination she faced as a woman, and ...

The UK-US deal does not resolve every challenge – no single agreement could. But it marks a meaningful step toward restoring ...